Proposed Diagnostic Criteria and Management of Marburg Variant Multiple Sclerosis: A Meta-analysis
Matthew Roberts1, Muhammad Abdullah1, Tania Reyna1
1Neurology, University of Texas Health San Antonio
Objective:

To propose diagnostic criteria and evidence-based treatment guidelines for Marburg, a life-threatening variant of multiple sclerosis (MS).

Background:

The rare Marburg variant of MS is characterized by life-threatening severity, a fulminant disease course, and poor response to therapy. Due to its rarity, no diagnostic criteria or standards of care have been established. We conducted a meta-analysis of prior cases of Marburg to identify both diagnostic criteria and evaluate the effectiveness of the most used treatment modalities.  

Design/Methods:

A PubMed database search was performed for primary reports of Marburg MS. The most used treatment modalities were included for pooled analysis of the primary outcome, which was mean pre- vs. post-treatment change in expanded disability severity score (EDSS) grouped by treatment modality. EDSS scores not directly reported by the authors were independently extracted by multiple reviewers and a mixed effects model was used to determine interrater reliability. Cases were quantitatively and qualitatively reviewed to produce formal diagnostic criteria. 

Results:

Of the 349 studies screened, 35 cases met inclusion criteria. The presenting symptoms included hemiplegia (77%), cranial neuropathies (57%), acute encephalopathy (51%), sensory changes (49%), and ataxia (37%). As a primarily monophasic illness, though 81% met radiographic criteria for dissemination in space, only 41% met full McDonald Criteria for MS. 20% of patients relapsed, while oligoclonal bands were observed in 33%. Overall mortality was 37%. Among the most commonly used treatment modalities, only high dose induction cyclophosphamide (HiCy) therapy was associated with significant improvement in EDSS. In contrast, steroids and/or plasmapheresis only, low-dose cyclophosphamide, and mitoxantrone were not associated with improved outcomes.

Conclusions:

Given the rapidly progressive nature of Marburg variant MS, early recognition and treatment are of paramount importance. This study is the first to propose diagnostic criteria and evidence-based treatment guidelines for the disease. Among treatment modalities, HiCy therapy appears to be the most effective.

10.1212/WNL.0000000000206694